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Influence of Combination Therapy with Immune Modulators on
Anti-TNF Trough Levels and Antibodies in Patients with IBD
Tamara van Schaik, BSc, Jeroen P. W. Maljaars, MD, PhD, Rajiv K. Roopram, BSc, Marthe H. Verwey, MA,
Nienke Ipenburg, MA, James C. H. Hardwick, MD, PhD, Roeland A. Veenendaal, MD, PhD,
and Andrea E. van der Meulen-de Jong, MD, PhD
Background: It is important to identify factors that can reduce the incidence of immunogenicity against anti-tumor necrosis factor medication in
patients with inflammatory bowel disease. The objective of our study was to evaluate the influence of cotreatment with immune modulators (IMs) on
trough levels (TLs) and antidrug antibodies.
Methods: The records of all patients with inflammatory bowel disease at the Leiden University Medical Center who received either adalimumab or
infliximab (IFX) in the year 2011 and/or 2012 (n ¼ 352) were retrospectively evaluated about the assessment of TL and antibodies and use of IM.
Results: Two hundred seventeen patients were included (108 patients IFX; 109 patients adalimumab). Mean TL in the IFX group was higher in the
combination therapy group compared with the monotherapy group, 4.6 versus 7.5 mg/mL, P ¼ 0.04. In the adalimumab group, the difference was not
significant. In patients with IFX monotherapy, the incidence of antibody formation was higher compared with patients with combination therapy (29.8% versus
5.7%, P ¼ 0.001). IFX patients with a suboptimal dose of IM had a higher TL compared with patients who had an optimal dose, P ¼ 0.02. The incidence of
antibody formation was lower in IFX patients who immediately started with IMs compared with patients who did not (33.3% versus 66.7%, P ¼ 0.04).
Conclusions: The influence of combination therapy with IM on TL and antibodies to anti-tumor necrosis factor medication was significant for
IFX-treated patients. Patients who started combination therapy immediately developed antibodies less often than patients who started later with
concomitant medication.
(Inflamm Bowel Dis 2014;20:2292–2298)
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I n patients with inflammatory bowel disease, biologicals, such asinfliximab (IFX) and adalimumab (ADA), are part of the standard
treatment regimen.1–3 IFX is a chimeric and ADA is a fully human-
ized monoclonal immunoglobulin G1 antibody against tumor
necrosis factor (TNF) that specifically bind to TNF-a.4,5 Several
randomized controlled trials have demonstrated the effectiveness of
these biologicals as compared with placebo treatment.3,4,6–8
Treatment with anti-TNF agents can result in immunogenicity
and the formation of antidrug antibodies against these agents.9 Anti-
body formation has been associated with a shorter duration of clinical
response,9 lower trough levels (TLs) of anti-TNF,7 and a higher
incidence of infusion reactions.9,10 Still, the importance of antibody
formation is disputed because other factors than anti-TNF-a antibod-
ies could influence TLs and loss of response, such as variability in the
rate of elimination (clearance).11 Besides, some studies have not
shown differences between antibody-positive and antibody-negative
patients regarding rates of remission, response, endoscopic improve-
ment, C-reactive protein, and colectomy.10,12,13 However, detectable
serum IFX concentrations have consistently been associated with
clinical remission and endoscopic improvements, and an undetectable
trough serum IFX level predicts an increased risk for colectomy.13
A universally used strategy to reduce antibody formation is
maintenance treatment instead of episodic treatment with IFX.10,13
Another strategy to reduce antibody formation is to combine anti-
TNF treatment with immune modulators (IMs).9,10 Furthermore,
early combined immunosuppression (IFX + azathioprine) is also
more effective for induction of remission and reduction of corti-
costeroid use compared with conventional step-up therapy.14
However, the data on the importance of antibody formation and
the efficacy of cotreatment with IM to reduce this phenomenon
have predominantly been performed on IFX: the influence of
combination therapy with IM on TLs and antibodies in patients
treated with ADA has been poorly investigated.15
We therefore performed a retrospective study on optimization
of anti-TNF treatment using IM, using data from our tertiary referral
centre. The objective of our study was, first, to evaluate the influence
of cotreatment with IM in patients using anti-TNF on anti-TNF TL
and antibodies. Second, because IM are frequently given in sub-
optimal dose because of due to side-effects, we investigated whether
a suboptimal dose influenced TL or antibody formation.
Received for publication June 11, 2014; Accepted July 31, 2014.
From the Department of Gastroenterology, Leiden University Medical Center,
Leiden, the Netherlands.
The authors have no conflicts of interest to disclose.
Reprints: Andrea E. van der Meulen-de Jong, MD, PhD, Department of
Gastroenterology and Hepatology, C4P, Leiden University Medical Centre,
Albinusdreef 2, 2333 ZA Leiden, the Netherlands (e-mail: ae.meulen@lumc.nl).
Copyright © 2014 Crohn’s & Colitis Foundation of America, Inc.
DOI 10.1097/MIB.0000000000000208
Published online 16 September 2014.
2292 | www.ibdjournal.org Inflamm Bowel Dis  Volume 20, Number 12, December 2014
METHODS
Study Design and Patients
A retrospective search of medical records was performed of
all patients with inflammatory bowel disease (IBD) who received
either ADA or IFX in the year 2011 and/or 2012 at the Leiden
University Medical Center. Those patients with 1 or more assess-
ments of anti-TNF TLs or antibodies against anti-TNF testing were
included in the study and retrospectively evaluated. All laboratory
assessments concerning antidrug antibodies, TLs, and IM metab-
olites were obtained from the medical record, and all assessments
performed during the period January 2010–March 2013 in our
cohort were included. Besides these laboratory values, demo-
graphic and clinical characteristics were collected from the elec-
tronically medical records. Characteristics included gender, date of
birth, body weight, diagnosis (Crohn’s disease or ulcerative colitis),
date of diagnosis, smoking status, anti-TNF use, concomitant med-
ication, date of anti-TNF and IM initiation, medication dose, clin-
ical response, and C-reactive protein values. Patients were
considered as being treated with combination therapy with IMs if
they were at least treated for a period of 10 weeks before laboratory
date or stopped no longer than 4 weeks before laboratory date.
For all TL and antibodies to anti-TNF assessments, the
reason for ordering the test, date of testing, date of follow-up, and
changes to medication were recorded. TL and antibody concen-
trations were ordered in patients with IBD as decided by the
treating physician. Reasons could be: (1) complaints/loss of
response, (2) to titrate the dose actively, (3) for clinical interest,
and (4) to control TL after a medication change based on previous
TL results (follow-up TL assessment). Complaints/loss of response
could consist of clinical worsening of symptoms and/or objective
inflammation, the latter proven by elevated C-reactive protein or
endoscopic activity. The assessments of clinical interest were in
absence of clinical complaints (e.g., building up clinical experience,
interest because of possible medication stop in [near] future).
Patients who were lost to follow-up or died between 2011–
2012 and March 2013 were followed up until their last contact
moment or date of death.
Serum Testing
TL and antibodies were performed by Sanquin (Amster-
dam, the Netherlands) and reported in microgram per milliliter
and AE per milliliter, respectively. TL was defined as serum
concentration immediately before an IFX/ADA infusion. A
normal TL for IFX was defined as between 3 and 7 mg/mL,
a low TL as ,3 mg/mL, and a high TL as .7 mg/mL. A normal
TL for ADA remains unclear in clinical practice but we used the
same ranges as for IFX. Antidrug antibody levels for both IFX and
ADA were reported as either negative (,12 AE/mL) or positive
(.12 AE/mL).
The serum concentration of azathioprine, mercaptopurine,
and thioguanine is determined by measuring the 6-thioguanine
level in red blood cells. A normal concentration was defined as
being 460 to 900 pmol/8 · 108 red blood cells.
Furthermore, the optimal therapeutic dose was calculated
based on bodyweight, according to the following: azathioprine 2 to
2.5 mg/kg, 6-mercaptopurine 1 to 1.5 mg/kg, thioguanine 0.3 mg/
kg, and methotrexate$15 mg/wk. When the actual dose was below
this weight-based calculated dose, they were deemed to be subop-
timal. If 6-thioguanine levels had been measured more than once in
the same patient, the first measurement was included in this study.
Statistical Analysis
All statistical analyses were performed with SPSS (version 20;
SPSS, Inc., Chicago, IL). Demographic and baseline characteristics
were compared between groups with the use of the chi-squared test
for categorical variables and the independent sample t-test for
continuous variables. Trough serum levels were compared between
the monotherapy group and the combination therapy group by
using an independent sample t-test. The proportion of patients with
a positive antibody status was compared between the monotherapy
group and the combination therapy group by using a chi-squared
test. Similarly, in the subgroup analyses on dose and duration of
treatment with IM, we compared the 2 groups with the use of a chi-
squared test and an independent sample t-test.
RESULTS
Baseline Characteristics
A total of 352 anti-TNF users in 2011 and/or 2012 with IBD
were identified. In 217 patients, either anti-TNF TLs or anti-TNF
antibody levels had been measured at least once (TL: n ¼ 211 and/
or antibodies: n ¼ 203) during the period January 2010–March
2013 (Fig. 1). Baseline demographic and clinical characteristics
of the 217 patients are shown in Table 1 for IFX and in Table 2
for ADA. We compared the monotherapy group (n¼ 128) with the
FIGURE 1. Study design and number of patients. AB: number of patients
with antibody testing. Mono: Monotherapy group. Combi: Combination
therapy group. *Only tested on antibodies. +Only tested on TL.
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combination therapy group (n¼ 89). For IFX patients, body weight
and previous treatment with IM differed significantly between the 2
groups. For ADA patients, age at the time of initial test, current
duration of anti-TNF use, and previous treatment with IM differed
significantly between the 2 groups.
Trough Levels
In 211 of the 217 patients, at least 1 TL was determined. Of
these 211 patients, 102 were treated with IFX and 109 were
treated with ADA.
TL in patients treated with IFX was low in 43 patients
(42.2%), normal in 25 patients (24.5%), and high in 34 patients
(33.3%). For patients treated with ADA, these numbers were 10
(9.2%), 26 (23.9%), and 73 (67.0%), respectively. Most of the
laboratory TL assessments were requested because of loss of response
(62.5%), followed by clinical interest (27.6%) and titration (9.7%).
However, TL did not differ between the different indications (Fig. 2).
In Figure 3, outcome of TL for all TL patients (n ¼ 211),
IFX (n ¼ 102), and ADA (n ¼ 109) are shown. In the IFX group,
mean TL was significantly higher in patients treated with com-
bination therapy compared with the patients treated with mono-
therapy (7.5; SD ¼ 7.34 mg/mL versus 4.58; SD ¼ 6.66 mg/mL,
P ¼ 0.04). No such difference was found in the ADA group
(11.47; SD ¼ 8.18 mg/mL versus 13.10; SD ¼ 11.97 mg/mL, not
significant).
Antibody Formation
Results for antibodies were available for 203 patients (100
IFX and 103 ADA). In patients with IFX, combination therapy
(n ¼ 47) reduced the incidence of antibody formation compared
with patients with monotherapy (n ¼ 53); respectively (29.8%
versus 5.7%, P ¼ 0.001, Fig. 4). No effect of combination therapy
was observed in the ADA patients (Fig. 4).
TLs and Antibodies: Effect of Previous IM Use
Of the 79 ADA monotherapy patients, 32 used IM during
their current ADA treatment episode. When comparing TL and
antibodies between patients who have previously used an IM
TABLE 1. Baseline Patient Characteristics for IFX
Characteristic Monotherapy (n ¼ 49) Combination Therapy (n ¼ 59) Total (n ¼ 108) Pa
Male, n (%) 18 (36.7) 31 (52.5) 49 (45.4) 0.100
Age (at the time of initial test), mean 6 SD, yr 41.1 6 15.1 38.1 6 13.1 39.5 6 14.0 0.289
Body weight, mean 6 SD, kg 66.2 6 14.4 75.5 6 15.7 71.3 6 15.7 0.002
Disease duration, mean 6 SD, yr 13.1 6 11.8 13.7 6 10.3 13.4 6 11.0 0.784
Age at diagnosis, mean 6 SD, yr 27.9 6 13.6 24.4 6 10.6 26.1 6 12.1 0.143
Type IBD, n (%) 0.728
Crohn’s disease 34 (69.4) 40 (67.8) 74 (68.5)
Ulcerative colitis 11 (22.4) 16 (27.1) 27 (25.0)
Indeterminate colitis 4 (8.2) 3 (5.1) 7 (6.5)
Smoking status, n (%) 0.428
Current 9 (18.4) 11 (18.6) 20 (18.5)
Former 14 (28.6) 12 (20.3) 26 (24.1)
Never 23 (46.9) 27 (45.8) 50 (46.3)
Unknown 3 (6.1) 9 (15.3) 12 (11.1)
Anti-TNF use
Current duration, mean 6 SD, yr 2.7 6 1.7 2.9 6 2.3 2.8 6 2.0 0.618
Previous anti-TNF treatment, n (%) 23 (46.9) 24 (40.7) 47 (43.5) 0.514
IM, n (%)
AZA — 41 (69.5) —
6-MP — 8 (13.6) —
6-TG — 0 (0) —
MTX — 10 (16.9) —
Previous treatment, n (%) 46 (93.9) 36 (61.0) 82 (75.9) 0.000
Other concomitant medication, n (%) 0.781
Corticosteroids 9 (18.4) 9 (15.3) 18 (16.7)
5-Aminosalicylates 6 (12.2) 7 (11.9) 13 (12.0)
aP values for monotherapy versus combination therepy. P values were calculated with the use of independent sample t-test and chi-squared test.
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TABLE 2. Baseline Patient Characteristics for ADA
Characteristic Monotherapy (n ¼ 79) Combination Therapy (n ¼ 30) Total (n ¼ 109) Pa
Male, n (%) 25 (31.6) 14 (46.7) 39 (35.8) 0.144
Age (at the time of initial test), mean 6 SD, yr 41.6 6 12.0 35.7 6 12.1 40.0 6 12.3 0.027
Body weight, mean 6 SD, kg 72.4 6 19.2 67.2 6 15.4 71.0 6 18.3 0.145
Disease duration, mean 6 SD, yr 16.0 6 10.3 12.7 6 8.7 15.1 6 10.0 0.096
Age at diagnosis, mean 6 SD, yr 25.6 6 9.3 23.0 6 7.4 24.9 6 8.9 0.143
Type IBD, n (%) 0.363
Crohn’s disease 70 (88.7) 29 (96.7) 99 (90.8)
Ulcerative colitis 5 (6.3) 1 (3.3) 6 (5.5)
Indeterminate colitis 4 (5.1) 0 (0) 4 (3.7)
Smoking status, n (%) 0.837
Current 16 (20.3) 5 (16.7) 21 (19.3)
Former 20 (25.3) 6 (20.0) 26 (23.9)
Never 37 (46.8) 17 (56.7) 54 (49.5)
Unknown 6 (7.6) 2 (6.7) 8 (7.3)
Anti-TNF use
Current duration, mean 6 SD, yr 2.6 6 1.4 1.8 6 1.1 2.4 6 1.4 0.005
Previous anti-TNF treatment, n (%) 52 (65.8) 22 (73.3) 74 (67.9) 0.453
IM, n (%) — —
AZA — 18 (60.0) —
6-MP — 7 (23.3) —
6-TG — 0 (0) —
MTX — 5 (16.7) —
Previous treatment, n (%) 72 (91.1) 18 (60.0) 90 (82.6) 0.000
Other concomitant medication, n (%) 0.640
Corticosteroids 6 (7.6) 4 (13.3) 10 (9.2)
5-aminosalicylates 2 (2.5) 1 (3.3) 3 (2.8)
FIGURE 2. Indications for laboratory assessments with outcomes in IFX and ADA patients. LOR: Loss of response.
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during the current ADA episode (but not at the time of TL and/or
antibody status assessment) and IM nonusers, no differences were
observed in TLs (9.42; SD ¼ 6.25 mg/mL versus 12.73; SD ¼
9.0 mg/mL, respectively) and formation of antibodies (16.7%
versus 23.7%, respectively, P ¼ 0.477).
Similarly, in IFX patients, no difference was observed
in TLs (4.92; SD ¼ 7.4 mg/mL versus 4.85; SD ¼ 5.9 mg/mL,
P ¼ 0.975) and antibody formation (17.6% versus 29.6%, respec-
tively, P ¼ 0.371) between previous IM users, earlier during the
use of the current anti-TNF agent and IM nonusers.
Effect of IM Dose on TLs and
Antibody Formation
Of the 211 patients with known TL, 86 patients received
combination therapy with IMs at the time of TL assessment (Fig. 1).
IFX-patients with a suboptimal IM dose had a higher TL compared
with patients who were optimally dosed (9.81; SD ¼ 8.08 mg/mL
versus 5.36; SD ¼ 5.95 mg/mL; P ¼ 0.024), whereas for ADA, no
such difference was observed (data not shown).
In 82 patients who received combination therapy (n ¼ 89),
antibodies were measured (Fig. 1). The dosing of the IM did not
influence the incidence of antibody formation for patients using
IFX (n ¼ 53; suboptimal dosed IM versus optimal dosed IM;
8.0% versus 3.6%, not significant) nor for patients using ADA
([n ¼ 29]; 15.4% versus 18.75%, respectively; not significant).
The same was the case in patients with known 6-thioguanine
serum levels (5% versus 11%, not significant).
Timing of IM Therapy
We compared TL and formation of antibodies between
patients who started IM immediately after starting anti-TNF
medication and those who started later. No difference was
observed for both IFX (7.85; SD ¼ 7.87 mg/mL versus 6.35;
SD ¼ 5.33 mg/mL) and ADA (13.89; SD ¼ 11.46 mg/mL versus
FIGURE 3. Mean TL in patients with IBD in the total population and in a subanalysis for IFX and ADA. The numbers above the bars correspond to
the mean TL. The error bars correspond to the SD.
FIGURE 4. Incidence of antibodies to anti-TNF in monotherapy versus combination therapy in the total population and in a subanalysis for IFX and
ADA. The numbers above the bars correspond to the percentage antibodies.
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11.72; SD ¼ 13.25 mg/mL). Regarding IFX, the incidence of
antibody formation was lower in patients who started IM imme-
diately compared with patients who did not ([n ¼ 53]; 2.4%
versus 18.2%, respectively, P ¼ 0.044). This relationship was
not observed in patients using ADA ([n ¼ 29]; 30.0% versus
10.5%, respectively, not significant).
A total of 128 patients did not use IM at the time of TL
assessment. Ten patients did not receive any previous IM treatment.
In the remaining 118 patients, the main reason for stopping IM
previously was “intolerance” to the agent (20.4%), which could
consist of nausea, vomiting, headaches, dizziness, tiredness, sleep-
lessness, or general malaise. Other reasons were liver function test
abnormalities and pancreatitis (12.6%), infection (12.0%), step-
down therapy (12.0%), patient preference (11.0%), dermatological
side-effects (6.5%), leucopenia/anemia/thrombocytopenia (5.8%),
low efficacy (5.8%), miscellaneous (5.2%), joint and muscle com-
plaints (3.6%), and unknown (5.2%).
DISCUSSION
In this retrospective cohort of 217 patients, we evaluated
the influence of combination therapy with IM on TL and
antibodies to anti-TNF medication in patients with IBD. From
this study, we can draw a number of interesting conclusions:
First, in patients receiving ADA, no beneficial effect was
observed of IM comedication regarding TLs and antibody forma-
tion. This is in contrast to patients with IFX, where combination
therapy led to higher TLs and a lower presence of antibodies.
Second, in IFX patients receiving IM comedication, the
dose of the IM does not influence TLs or antibody formation.
Third, starting comedication together with IFX seems to be
beneficial, as these patients developed antibodies at a lower rate
than patients who started comedication later.
Presence of antidrug antibodies has been shown to reduce the
clinical efficacy of ADA.16 However, whether IM comedication
prevents formation of anti-ADA antibodies is uncertain. For
instance, Karmiris et al17 retrospectively studied 169 ADA patients,
of whom 62 used IM. In this study, IM comedication did not
influence development of antidrug antibodies or TL.17 In contrast,
in the prospective CLASSIC-II study, antibodies were only seen in
patients who were on ADA monotherapy, which would suggest
a preventive effect of IM.8 In our study in 109 patients using
ADA for an average period of over 2 years, no effect was observed
of using IM comedication on antibody formation or TLs. A large
part of the patients on monotherapy was on combination therapy
before the assessment of TL and antibodies. To rule out that pre-
vious IM use had a protective effect on TL and antibody formation,
we compared monotherapy patients who had and who had not used
IM during the current ADA period. No effect of previous IM use
was observed on TL and antibody formation.
One factor complicating the interpretation of this and other
studies is that presence of antibodies may be intermittent; patients
who are antibody-positive can convert back to antibody-negative
status.10 This may have affected results in the above-mentioned
articles and in our study. Another factor that could complicate the
interpretation is the fact that most anti-TNF monotherapy patients
have used an IM in the past (93.9% for IFX and 65.8% for ADA,
Tables 1 and 2) and also during current anti-TNF use (63% for
IFX and 45.1% for ADA).
In our study, we did not assess clinical response, and IM
comedication may improve clinical response, as was suggested in
a meta-analysis18 presented at the 2014 ECCO meeting. However,
this meta-analysis used primarily post-hoc data of prospective
studies and data from retrospective studies, which means that
these results should be interpreted with some caution. Because
no prospective studies have been performed that specifically
assess the benefit of IM comedication in patients using ADA,
our and other17,19 data suggest that there is no indication for
standard combination therapy in patients starting ADA.
In clinical practice, many patients are unable or unwilling
to tolerate the optimal weight-based dose of azathioprine or
6-mercaptopurine. The effects of IM use in patients using a sub-
optimal dose on TL and antibody formation have, to our knowledge,
not yet been described. Surprisingly, IFX patients who used
a suboptimally (based on weight) dosed IM had a significantly
higher TL than patients who were optimal dosed. No effect of
suboptimal dosing on antibody formation was observed in IFX
patients. These data demonstrate that in patients who were unable or
unwilling to tolerate the full dose of IM, a beneficial effect of a lower
IM dose may still be expected.
Cotreatment of IFX and an IM is standard practice in many
centers, and the benefits of IM cotreatment have been previously
demonstrated. Our study shows that IFX patients who immediately
started with IM had a lower incidence of antibodies compared with
patients who started later with IM. This indicates that early
combined immunosuppression is better than step-up therapy.
In conclusion, cotreatment with an IM seems beneficial for
patients on IFX and should be started simultaneously with the start
of IFX. In patients who were unable or unwilling to tolerate the full
dose of IM, a beneficial effect of a lower IM dose was still observed.
In contrast, no benefit of IM cotreatment was observed in
the ADA-treated patients. Given the results of this and other
studies, there is no indication for standard IM comedication in
patients using ADA.
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